HSBC Downgrades AstraZeneca to Hold AstraZeneca (NASDAQ:AZN) shares moved lower on Monday after HSBC downgraded the ...
By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter ...
GlobalData on MSN
Sino and AstraZeneca sign licence agreement for TQC3721
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...
July 9 () - AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis, failed to meet the ...
AstraZeneca's stock tumbled after the pharmaceutical company said its Wainua drug failed to meet the primary target in a late-stage clinical trial for heart disease, denting investor hopes for ...
Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results